LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $5.486 million which beat the analyst consensus estimate of $2.373 million by 131.17 percent. This is a 9.72 percent increase over sales of $5.000 million the same period last year.